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ABSTRACT
Introduction: Depressive disorders are among the
most common psychiatric disorders in children and
adolescents, and have adverse effects on their
psychosocial functioning. Questions concerning the
efficacy and safety of antidepressant medications in the
treatment of depression in children and adolescents,
led us to integrate the direct and indirect evidence
using network meta-analysis to create hierarchies of
these drugs.
Methods and analysis: Seven databases with
PubMed, EMBASE, the Cochrane Library, Web of
Science, CINAHL, LiLACS and PsycINFO will be
searched from 1966 to December 2013 (updated to
May, 2015). There are no restrictions on language or
type of publication. Randomised clinical trials
assessing first-generation and newer-generation
antidepressant medications against active comparator
or placebo as acute treatment for depressive disorders
in children and adolescents (under 18 years of age)
will be included. The primary outcome for efficacy will
be mean improvement in depressive symptoms, as
measured by the mean change score of a depression
rating scale from baseline to post-treatment. The
tolerability of treatment will be defined as side effect
discontinuation, as defined by the proportion of
patients who discontinued treatment due to adverse
events during the trial. We will also assess the
secondary outcome for efficacy (response rate),
acceptability (all-cause discontinuation) and suicide-
related outcomes. We will perform the Bayesian
network meta-analyses for all relative outcome
measures. Subgroup analyses and sensitivity analyses
will be conducted to assess the robustness of the
findings.
Dissemination: The network meta-analysis will
provide useful information on antidepressant treatment
for child and adolescent depression. The results will be
disseminated through peer-reviewed publication or
conference presentations.
Trial registration number: PROSPERO
CRD42015016023.
BACKGROUND
Depressive disorders in children and adoles-
cents are a major public health problem,
demonstrated by the disorders ranking as the
third most important in the estimation of
disease burden.1 The prevalence of experien-
cing at least one episode of major depression
before adulthood is estimated to be approxi-
mately 1–2% for children (6–12 years old),
and 2–5% for adolescents (13–18 years old).2
Strengths and limitations of this study
▪ This Bayesian network meta-analysis can inte-
grate direct evidence with indirect evidence from
multiple treatment comparisons to estimate the
interrelations across all treatments.
▪ We will comprehensively assess the efficacy,
tolerability, acceptability and suicide-related out-
comes of first-generation and newer-generation
antidepressant medications for depression in
children and adolescents.
▪ Several subgroup and sensitivity analyses will
address some clinically relevant questions.
▪ This method comprehensively synthesises data
to provide a clinically useful summary that can
guide treatment decisions and guideline
development.
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The course of major depression in young people is
often characterised by frequent recurrence, protracted
episodes and comorbid psychiatric disorders.3 The con-
sequences of an untreated episode of major depression
in young people are likely to be serious impairment in
social functioning, for example, poor school achieve-
ment, or relational problems with family members and
peers.4 A report from the American Academy of Child
and Adolescent Psychiatry (AACAP) suggested that
depression is responsible for over 500 000 suicide
attempts by children and adolescents a year, with most
of this group diagnosed with treatable forms of mental
illness.5 6 Thus, early recognition, diagnosis and treat-
ment of depression in children and adolescents is an
important strategy for curbing the rising rate of youth
suicide, seen in many developed and advanced develop-
ing nations.7
Since the late 1960s, first-generation antidepressants,
for example, tricyclic antidepressant (TCA) drugs, have
been used to treat depressive symptoms in young
patients.8 In the US, the use of antidepressant medica-
tion in children and adolescents grew 3–10-fold between
1987 and 1996.9 The efficacy of TCAs has been investi-
gated in 13 randomised placebo-controlled trials,10
which showed marginal evidence to support the use of
TCAs in the treatment of depression in only adolescents.
However, methodological deficiencies in these trials,
including small sample sizes and diagnostic heterogen-
eity, restrict statistical inference and generalisability of
the findings. At the same time, cardiovascular effects
and overdose-related mortality associated with TCA use
have greatly limited their utility in clinical practice.11 12
Nevertheless, the TCA nortriptyline is still approved by
the Food and Drug Administration (FDA) for the treat-
ment of depression in adolescents and adults.13
In recent decades, newer-generation antidepressants,
including second-generation antidepressants (eg, select-
ive serotonin reuptake inhibitors (SSRIs)) and third-
generation antidepressants (eg, serotonin–norepineph-
rine reuptake inhibitors (SNRIs)), have been widely
used for the treatment of depression in children and
adolescents.14 The frequency of prescription of SSRIs
and SNRIs in children and adolescents has progressively
increased.15 In European countries, there has been a
doubling of SSRI use over a 4-year period.16 However,
only fluoxetine was approved by the US FDA for treating
depression in children and adolescents in January
2003.17 In the same year, concerns about the increased
risk of suicide and suicide attempts with SSRIs were first
raised.18 In September 2004, the FDA cautioned practi-
tioners in the use of antidepressant medications in chil-
dren and adolescents.19 Similar warnings were issued by
other health regulatory agencies.20–22 Thus, concerns
about this issue have refocused attention on the ques-
tion of how effective antidepressant medications are in
treating youth depression.
Nonetheless, currently, no published meta-analysis has
combined direct and indirect evidence for the use of
antidepressant medications on children and adolescents,
though it is an important study to perform, given the con-
flicting results regarding the efficacy and tolerability of
various antidepressant medications in this age group, and
lack of head-to-head trials of such drugs.23–25 For these
reasons, we will employ a network meta-analysis—a meth-
odological approach that allows the simultaneous compari-
son of multiple psychotherapeutic interventions within a
single analysis, while preserving randomisation.26 This
approach will be used to integrate direct evidence (from
studies directly comparing interventions) with indirect evi-
dence (information about two treatments derived via a
common comparator) from multiple treatment compari-
sons to estimate the interrelations across all treatments.27
We have previously compared the efficacy and acceptabil-
ity of psychotherapies for depression in children and
adolescents,28 and the augmentation agents for
treatment-resistant depression in adults29 in this way. The
aim of the network meta-analysis of randomised controlled
trials (RCTs) is to systematically reanalyse the efficacy, tol-
erability, acceptability and suicide risk of both first-
generation and newer-generation antidepressant medica-
tions against active comparator or control conditions, in
the treatment of child and adolescent depression.
METHODS
Criteria for included studies
Types of studies
Any prospective RCTs, including cross-over design and
cluster randomised trials, will be included. However,
quasi-randomised trials (eg, those allocating using alter-
nate days of the week) will be excluded. Trials with sample
sizes smaller than 10 will be excluded in this review.
Types of participants
Children and adolescents (aged from 6 to 18 years when
they initially enrolled in the trials) with a primary diag-
nosis of current major depressive disorder according to
standardised diagnostic interviews, for example, the
Diagnostic and Statistical Manual of Mental Disorders
(DSM)30–32 or the International Classification of
Diseases (ICD),33 34 will be included. Where a trial con-
tains a portion of participants who are over 18 years of
age, we will contact the trial authors in order to obtain
data for only those participants within our age range. We
will exclude trials focusing on child or adolescent
bipolar disorder, but will include trials involving patients
with comorbid general psychiatric disorders, such as
attention deficit hyperactivity disorder, anxiety disorder
and substance-related disorder. Also, we will not exclude
trials in which participants have a diagnosis of psychotic
depression; these participants will be considered within
a separate subgroup analysis. However we will exclude
trials in which participants have a diagnosis of
treatment-resistant depression, because these patients
tend to have a different treatment response compared
with patients with non-resistant depression.
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Types of interventions
RCTs comparing any first-generation and newer-
generation antidepressant drug against active compara-
tor or placebo for treatment of depression in children
and adolescents will be included. Trials comparing the
same type of antidepressant but at different therapeutic
dose (fixed or flexible dose) and different treatment
duration will be considered as the same node in the
network analysis. We will exclude trials involving combin-
ation therapy (ie, combination of antidepressant medica-
tions, combination of antidepressant medication with
psychotherapy, or other non-psychotherapeutic interven-
tions); however, trials will be considered as eligible if the
concomitant psychotherapy is not predefined in the
study.
Types of outcome measures
The acute phase will be defined as from 4 to 16 weeks,
and if a trial presents data beyond 16 weeks or for more
than one time period within our predefined acute phase
periods, we will take the 8-week or close to 8-week time
point.35 We will exclude trials with treatment duration of
<4 weeks. Where depression symptoms are measured
using more than one depression scale in a trial, we will
extract data from the depressive scales on the basis of a
hierarchy of rating scales. This hierarchy will be based
on psychometric properties and appropriateness for use
with children and adolescents, and for consistency of
use across trials (referred from the Hetrick14 et al study)
(table 1). The Children’s Depression Rating Scale
Revised (CDRS-R)36 is adapted for children and adoles-
cents from the Hamilton Depression Rating Scale
(HAMD),37 a tool validated and commonly used in
adult populations.38 Both the CDRS-R and HAMD have
good reliability and validity.38 The Beck Depression
Inventory (BDI)39 and the Children’s Depression
Inventory (CDI)40 are the most commonly used among
depression symptom severity self-rated scales and are
ranked second highest in the hierarchy.
1. Overall efficacy
The primary outcome for efficacy will be mean
improvement in depressive symptoms, as measured
by the mean change score of depression rating
scales (self-rated or assessor-rated) from baseline to
end point.
The secondary outcome for efficacy will be
response in depressive symptoms, as estimated by
the proportion of patients who achieved a decrease
of a certain percentage (eg, a reduction of 50% or
more) in depression rating score.41 When ‘response’
is not reported, we will use ‘remission’, if available.
Remission will be defined as the proportion of
patients who achieved a depression rating score
below the published threshold (eg, CDRS-R≤28).41
2. Overall tolerability
The tolerability of treatment will be defined as side
effect discontinuation in this review, as defined by the
proportion of patients who discontinued treatment due
to adverse events during the study.
3. Overall acceptability
The acceptability of treatment will be defined as all-
cause discontinuation, as measured by the proportion of
patients who discontinued treatment (during the deliv-
ery of the intervention) up to the post-intervention time
point.
4. Suicide-related outcomes
Suicide-related dichotomous and continuous out-
comes will be measured. If data are available, we will
extract the number of participants with suicide-related
events (combined suicidal ideation and suicidal behav-
iour) during the acute treatment, as measured on a stan-
dardised, validated and reliable rating scale, or reported
cases of suicidality.42 In addition, we will also collect data
on suicidal ideation as a continuous outcome where a
standardised, validated and reliable rating scale, such as
the Suicidal Ideation Questionnaire-Junior High School
version (SIQ-JR),43 has been used.
Data sources and search strategy
Seven electronic databases (PubMed, EMBASE, the
Cochrane Library, Web of Science, CINAHL, LiLACS
and PsycINFO) will be searched from 1966 to December
2013 (updated to May, 2015), with Medical Subject
Headings (MeSH) and text words: ‘depress*’ or ‘dys-
thymi*’ or ‘mood disorder*’ or ‘affective disorder*’ and
‘selective serotonin reuptake inhibitor*’ or ‘SSRIs’ or
Table 1 Hierarchy of depression symptom severity
measurement scales
Hierarchy
Depression symptom
severity measurement
scales Abbreviation
1 Children’s Depression Rating
Scale
CDRS
2 Hamilton Depression Rating
Scale
HAMD
3 Montgomery Asberg
Depression Rating Scale
MADRS
4 Beck Depression Inventory BDI
5 Children’s Depression
Inventory
CDI
6 Schedule for Affective
Disorders and Schizophrenia
for School Aged Children
K-SADS
7 Mood and Feeling
Questionnaire
MFQ
8 Reynolds Adolescent
Depression Scale
RADS
9 Bellevue Index of Depression BID
10 Child Depression Scale CDS
11 Centre for Epidemiologic
Studies Depression Scale
CESD
12 Child Assessment Schedule CAS
13 Child Behaviour Checklist—
Depression
CBCL-D
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‘serotonin norepinephrine reuptake inhibitor*’ or
‘SNRIs’ or ‘noradrenergic and specific serotonergic anti-
depressants’ or ‘NaSSA’ or ‘citalopram’ or ‘fluoxetine’
or ‘paroxetine’ or ‘sertraline’ or ‘escitalopram[’ or ‘flu-
voxamine’ or ‘venlafaxine’ or ‘duloxetine’ or ‘milnaci-
pran’ or ‘reboxetine’ or ‘bupropion’ or ‘mirtazapine’ or
‘tricyclic’ or ‘amersergide’ or ‘amineptine’ or ‘amitriptyl-
ine’ or ‘amoxapine’ or ‘butriptyline’ or ‘chlorpoxiten’
or ‘clomipramine’ or ‘clorimipramine’ or ‘demexipti-
line’ or ‘desipramine’ or ‘dibenzipin’ or ‘dothiepin’ or
‘doxepin’ or ‘imipramine’ or ‘lofepramine’ or ‘melitra-
cen’ or ‘metapramine’ or ‘nortriptyline’ or ‘noxiptiline’
or ‘opipramol’ or ‘protriptyline’ or ‘quinupramine’ or
‘tianeptine’ or ‘trimipramine’ and ‘adolesc*’ or ‘child*’
or ‘boy*’ or ‘girl*’ or ‘juvenil*’ or ‘minors’ or ‘paedia-
tri*’ or ‘pediatri*’ or ‘pubescen*’ or ‘school*’ or
‘student*’ or ‘teen*’ or ‘young’ or ‘youth*’. Also,
ClinicalTrials.gov, WHO’s trial portal, and US FDA
reports will be reviewed. There are no restrictions on
language or type of publication. Additional studies will
be searched in the reference lists of all identified publi-
cations including relevant meta-analyses and systematic
reviews. All relevant authors and principal manufac-
turers will be contacted to supplement incomplete
reports of the original papers or to provide new data for
unpublished trials.
Study selection
Two reviewers (BQ and YL) will independently scan cita-
tions at the title/abstract level identified from the search
strategies and then obtain potentially relevant studies in
full text, and determine whether to include them by the
same eligibility criteria. Besides, the references of rele-
vant reviews and included trials will also be checked by
the two reviewers. The reasons for exclusion of trials will
be reported in the characteristics of excluded studies
tables. Any disagreements will be resolved by a third
review author (XZ).
Data extraction and risk of bias assessment
Two independent reviewers (YL, BQ) will independently
extract the key trial parameters using a standardised
data abstraction form and assess the risk of bias. The
standardised data extraction forms will include the trial
characteristics (eg, first listed author, publication year,
journal, country, institution and sponsor), patient
characteristics (eg, diagnostic criteria for depression, the
type of patients, the number of patients, level of depres-
sive symptoms, comorbidities, the age of patients and
the gender of patients), intervention details (eg, anti-
depressant type, dose of antidepressant and the duration
of treatment) and outcome measures (efficacy, tolerabil-
ity, acceptability and suicide-related outcome). The risk
of bias in trials will be assessed by the Cochrane risk of
bias tool.42 Trials attracting a rating of high risk of bias
in one or more domains will be considered as ‘high
risk’, low risk of bias in all domains as ‘low risk’ and one
or more unclear risk of bias in each domain as ‘unclear
risk’.42 Any disagreements will be resolved by a third
review author (XZ). In addition, we will calculate the
inter-rater reliability of the two raters.
Data synthesis and analysis
We will perform Bayesian network meta-analysis to
compare the relative outcomes of different antidepres-
sant medications and placebo with each other from the
median of the posterior distribution.26 27 The pooled
estimates of standardised mean difference (SMD) with
95% credible intervals (CrIs) will be calculated for the
continuous outcomes; and ORs with 95% CrIs will be
calculated for the categorical outcomes. The SMD is
that the difference in means (MD) of change scores
between the two groups divided by the pooled SD of the
measurements, with a negative SMD value, indicates
greater symptomatic relief. In the presence of minimally
informative priors, CrIs can be interpreted similarly to
CIs, and at conventional levels of statistical significance a
two sided p<0.05 can be assumed if 95% CrIs do not
include 0. If means and SDs are not provided, we will
calculate them from the p value or other statistical
indices as described elsewhere.44 45 Results from
intention-to-treat analysis (ITT) or modified ITT will be
preferred over results from completer analyses, while we
will also consider the data set for the means and SDs
that are presented in the literature.
The pooled estimates will be obtained using the
Markov Chains Monte Carlo method. Two Markov chains
will be run simultaneously with different arbitrarily
chosen initial values. To ensure convergence, trace plots
and the Brooks-Gelman-Rubin statistic will be assessed.46
Convergence will be found to be adequate after running
50 000 samples for both chains. These samples will be
then discarded as ‘burn-in’, and posterior summaries will
be based on 100 000 subsequent simulations. The node
splitting method will be used to calculate the inconsist-
ency of the model, which separates evidence on a particu-
lar comparison into direct and indirect evidence.47
Probability values will be summarised and reported as
surface under the cumulative ranking curve (SUCRA)
and rankograms, a simple transformation of the mean
rank used to provide a hierarchy of the treatments and
accounts for both the location and the variance of all
relative treatment effects.48 Network meta-analysis will be
performed using the WinBUGS software package
(V.1.4.3, MRC Biostatistics Unit, Cambridge, UK) with
random-effects models for multiarm trials. The other
analyses will be performed and presented by the Stata
V.11.0 and R 2.11.1 software packages.
Subgroup analyses
The antidepressant medications will be coded according
to clinical characteristics, risk of bias and sample size.
We will conduct the subgroup analyses of data in
primary outcome for efficacy. We will perform the fol-
lowing subgroup analyses by using the meta-regression
model, and calculate Somer’s D (a correlation
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coefficient for a dichotomous and an ordinal variable):49
(1) sex ratio (male-to-female ratio >1 vs male-to-female
ratio <1); (2) age group; (3) treatment duration; (4)
severity of depressive symptom (mild-to-moderate vs
moderate-to-severe); (5) comorbid general psychiatric
disorders (with vs without comorbidity); (6) risk of bias
(‘high risk’ literature vs ‘unclear and low risk’ litera-
ture); (7) sample size; (8) company sponsor (with vs
without sponsor); and (9) the type of trials (published
literature vs unpublished literature). When there is the
limitation of a small number of comparisons for some
potential modifiers in carrying out subgroup analyses on
these variables, we will perform the sensitivity analyses by
omitting specific trials from the overall analysis.
Other analyses
Funnel plot analyses will be performed to check for pub-
lication bias. Moreover, we will carry out meta-regression
analyses to investigate the effect of sponsorship or year
published on outcome estimate.
Ethics and dissemination
This network meta-analysis does not need ethical
approval, as data used here are not individual or private.
The analysis will be published in a peer-reviewed
journal. The results will provide a general overview, and
evidence of efficacy and safety of antidepressant medica-
tions for depression in children and adolescents. The
results will also have implications for clinical practice
and further research.
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